Posted in

Europe’s First National Lung Cancer Screening Program

•Posted inRadiology

The Croatian National Lung Cancer Screening Program represents a groundbreaking public health initiative. As the first fully integrated national model within the European Union, it offers a replicable framework for countries like India facing a similar burden of late-stage lung cancer diagnosis. Croatia launched this multidisciplinary effort to combat its high lung cancer mortality, a leading cause of cancer-related death globally. Furthermore, the program’s innovative design incorporates advanced technologies and a unique operational structure, demonstrating the feasibility of large-scale early detection.

Key Technological Features in Lung Cancer Screening

The program incorporated modified International Early Lung Cancer Action Program (I-ELCAP) criteria for nodule management. Lung Cancer Screening relies heavily on Low-Dose Computed Tomography (LDCT). Consequently, accurate nodule assessment is essential. The Croatian model utilizes artificial intelligence (AI) to perform volumetric analysis on the LDCT scans. This approach is superior to simple diameter measurement because volume doubling time (VDT) provides a more accurate measure of a nodule’s growth rate. Similarly, AI-assisted reading can significantly reduce the radiologist’s workload and help differentiate between benign and malignant lesions.

The Croatian Integrated Model and Workforce Role

This screening program is fully integrated into the existing Croatian healthcare infrastructure and is completely reimbursed for participants. A key operational feature assigns a crucial role to general practitioners (GPs). They are responsible for identifying and referring high-risk individuals for screening. This GP-centered recruitment model ensures nationwide deployment, promoting equitable access. The initial results, spanning from October 2020 to August 2025, show high participation. Over 50,000 individuals were screened, which resulted in more than 70,000 LDCT scans. Approximately 4.5% of participants had positive results requiring further follow-up.

Clinical Relevance of the Croatian Lung Cancer Screening Model

The Croatian experience provides a valuable blueprint for public health systems worldwide. Since many countries, including India, lack a formal national screening program, this model addresses critical operational and logistical challenges. Therefore, incorporating AI and LDCT is crucial, especially when tackling unique regional challenges, such as a high prevalence of tuberculosis (TB) and varied risk factors like bidi smoking. Experts are urging a focus on risk stratification and multi-disciplinary team (MDT) management, echoing the comprehensive nature of the Croatian design.

Frequently Asked Questions

Q1: What is the core innovation of the Croatian National Lung Cancer Screening Program?

The program is the EU’s first fully integrated national screening effort. Its key innovation is the combination of GP-centered recruitment, full reimbursement, and advanced technology, including AI-assisted volumetric analysis of LDCT scans and modified I-ELCAP criteria.

Q2: What were the main results of the program’s initial operational phase (Oct 2020 – Aug 2025)?

During this period, the program screened over 50,000 participants. This process generated more than 70,000 LDCT scans. Out of the total participants, 4.5% had results requiring further clinical follow-up.

Q3: Why is the Croatian model relevant to other public healthcare systems?

The Croatian model demonstrates the feasibility of implementing a nationwide, fully reimbursed lung cancer screening program within a public healthcare system. Consequently, it provides a replicable, integrated framework for other countries working to reduce lung cancer mortality through early detection.

References

  1. Samaržija M et al. Design of the first national lung cancer screening program in the European Union: the Croatian Model. Eur Radiol. 2025 Dec 06. doi: 10.1007/s00330-025-12185-w. PMID: 41351704.
  2. Artificial Intelligence in Lung Cancer Screening: The Future Is Now – PMC – PubMed Central.
  3. Lung Cancer Screening India: Who Needs It & How. chestsurgeryindia.com.
  4. Newly published expert consensus recommends urgent shift to low-dose CT screening to detect lung cancer earlier – AstraZeneca India.
  5. Screening for Lung Cancer in India: Expert Opinion Statement – JAPI.
  6. Software using artificial intelligence for nodule and cancer detection in CT lung cancer screening: systematic review of test accuracy studies. bmj.com.
  7. AI-VDT can Help in Detecting Primary Lung Cancer – medRxiv.
  8. LDCT Screening in Smokers in India—A Pilot, Proof-of-Concept Study – PMC – NIH.
  9. Summary of different approaches to the evaluation of lung nodules. lungcancerpolicynetwork.com.
  10. AI-powered reading – Siemens Healthineers.
  11. Lung cancer screening in India: Preparing for the future using smart tools & biomarkers to identify highest risk individuals – PMC – PubMed Central.
  12. Guidelines for the management of pulmonary nodules detected by low-dose CT lung cancer screening 6th edition – PubMed Central.
  13. Baseline Screening Protocol, results and workup recommendations – I-ELCAP.
  14. International Early Lung Cancer Action Program: Screening Protocol – I-ELCAP.
  15. AI in Lung Cancer Screening: Enhancing Accuracy and Reducing Workload. healthmanagement.org.